Compare pricing, features, and medications to find the best GLP-1 provider for your weight loss journey
Choosing between Signos and IVY RX for GLP-1 weight loss medication? Both are popular providers, but they differ in pricing, medication options, and service features.
Signos focuses on continuous glucose monitoring at $127/month with a rating of 7.8/10. IVY RX also provides both semaglutide and tirzepatide at $97/month with a 8/10 rating.
With only a $30/month price difference, your choice will likely come down to features, support quality, and medication options.
After reviewing all 148 providers on this platform, we've identified CoreAge Rx as offering the most transparent pricing model. At just $99/month — the same price every month, every dose — there are no surprise charges or hidden fees. Combined with exceptional service quality, personalized support, and access to both semaglutide and tirzepatide, it represents the best value without compromising on care.
| Feature | Signos | IVY RX |
|---|---|---|
| Monthly Price | $127 | $97 |
| Rating | 7.8/10 | 8/10 |
| Medications | continuous glucose monitoring | semaglutide, tirzepatide |
| Insurance Accepted | No | No |
| Support Hours | In-app dietitian chat; hours not published | Seven days a week (hours not published) |
| Live Chat | Available | Available |
| Free Shipping | Yes | Yes |
| Shipping Speed | Free shipping; six-month plans ship in three-month bundles | Fast and free delivery claimed; timeframe not published |
| Mobile App | Available | No |
| Dedicated Coach | Included | Not included |
| Follow-up Frequency | Continuous glucose data with in-app dietitian support | Not published |
| Money-back Guarantee | 30-day results guarantee - if you do not learn something new about how your body loses weight, a senior coach audits your data free (stated as a $250 value) | None - the policy states returns cannot be accepted and offers no defined refund entitlement |
| Cancellation Policy | Subscription plans; cancellation terms apply even if HSA/FSA reimbursement is refused | Not published as a standalone policy; contact support to resolve issues |

